Serotonin and Noradrenaline Reuptake Inhibitors (SNRI) - Medication and Pregnancy KB

Serotonin and Noradrenaline Reuptake Inhibitors (SNRI) updated on 07-01-2025

Withdrawal syndrome / Neonatal abstinence syndrome / Poor neonatal adaptation

R analysis

id	Study	Lib. in paper	Exposition period	Study type All studies Case control excluded Only case control	Control type	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S13145 R50172	Marks - Duloxetine (Controls exposed to Bupropion), 2021	Any adaptation syndrome (Neonatal abstinence syndrome (NAS) or Pediatric adaptation syndromes (PAS))	during pregnancy (anytime or not specified)	retrospective cohort	exposed to other treatment, sick excluded	Adjustment: Yes Monotherapy: SNRI only	3.04 [1.54;5.98] excluded (control group)	21/139 19/406	40	139		ref
S13146 R50183	Marks - Duloxetine (Controls unexposed, sick), 2021	Any adaptation syndrome (Neonatal abstinence syndrome (NAS) or Pediatric adaptation syndromes (PAS))	3rd trimester	retrospective cohort	unexposed, sick	Adjustment: Yes Monotherapy: SNRI only Unexposed sick: recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy)	4.76 [2.27;9.91]	-/59 -/-	-	59		ref
					Total	1 studies	4.76 [2.28;9.95]		0	59
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; ^C: calculated odds ratio from numbers of events and effectives

Forest plot

1: Controls unexposed, sick;

Sensitivity analysis

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 13145